Cancer
Conditions
Brief summary
This study is a multicenter registry and is a prospective, observational, real-world study. Subjects were selected by clinicians for oral ONS nutritional intervention according to the actual clinical situation and the patient's wishes, and the observation period was 4 weeks. Subjects will receive a ready-to-drink marketed formula for special medical purposes with 4 flavors for free Food liquid preparation (Nengli Yijia, Nutricia in the Netherlands) for rounds of nutritional intervention, providing 1 flavor per week, 1-2 bottles per day, 4 flavors for a total of 28 days. The basic nutritional status and quality of life of patients were mainly evaluated at multiple time nodes before and after nutritional intervention. In order to improve the compliance of subjects, the all-round guardian platform (hereinafter referred to as the platform) by the China Initial Insurance Foundation was used during the intervention period to provide basic nutrition supervision, education and dietary guidance in routine nutrition support. Recruitment method: Convenient sampling method is adopted, from the beginning of recruitment to the target sample size. Follow-up period: After the start of the intervention, it will be carried out according to the plan of the follow-up task to the end of the intervention on the 28th day. The last telephone follow-up visit will complete on the 60th day after the end of the pre-end.
Interventions
DIETARY_SUPPLEMENTFortimel
In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients signed informed consent and volunteered to participate in the study * Patients diagnosed with colorectal cancer or primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring, undifferentiated adenocarcinoma) or NSCLC stage I-iv. by histopathological examination of primary biopsy * Cancer patients who were receiving chemoradiotherapy or immunotherapy were given 2 points for nutritional risk screening, and patients who met the conditions of ONS nutrition intervention were voluntarily enrolled to receive ONS nutrition intervention with Nertronecar * Basic reading and communication skills * The expected survival time is greater than 6 months
Exclusion criteria
* Combined cognitive dysfunction, mental disorder, impaired consciousness or unwillingness to partner * Contraindications with chemotherapy or immunotherapy * Prolonged bed rest, hemiplegia, or coma * Intolerance of allergies to nutrients or their main components, such as lactose or galactose * In the case of severe gastrointestinal symptoms of liver and kidney dysfunction, the serum creatinine glutamic pyruvic transaminase glutamic oxalacetic transaminase increases by more than 2.5 times, and the fasting blood glucose is over10mmol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| food intake change | One week before intervention and day 1, day 7, day 14, day 21, and day 28 of intervention. | calculated from recorded food intake through an online tool |
| weight | One week before intervention and day 1, day 14 and day 28 of intervention. | weight measured by body composition analyzer |
| fat-free mass index | One week before intervention and day 1, day 7,day 14,day 21, and day 28 of intervention. | fat-free mass index measured by body composition analyzer |
| skeletal muscle index | One week before intervention and day 1, day 7, day 14, day 21, and day 28 of intervention. | skeletal muscle index measured by body composition analyzer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 24h dietary intake | Day 1, day 14,and day 28 of intervention | — |
| Satiety | Day 1, day 14,and day 28 of intervention | VAS score |
| Gastrointestinal reactions | Day 1, day 14,and day 28 of intervention | enteral nutrition tolerance scale tool |
| Adherence to nutritional formulations | Day 1, day 14,and day 28 of intervention | using the patient's ONS compliance register |
Other
| Measure | Time frame | Description |
|---|---|---|
| Major complications during treatment | 28 days since the intervention. | General adverse reactions (dizziness, headache, fatigue and weakness, loss of appetite, nausea and vomiting, hair loss, dry mouth, dyspepsia, stomach discomfort, tissue edema, constipation, diarrhea, blood in the stool, etc.), nosocomial infection, respiratory failure, cardiovascular events (stroke, intracranial hemorrhage, cardiac arrest, myocardial infarction, etc.), radiation brain reactions, radiation pulmonary fibrosis, radiation pneumonitis, radiation pharyngitis, radiation esophagitis, radiation xerostomia, radiation otitis media, radiation mandibular arthritis, radiation neck skin atrophy, radiation caries, hearing loss, deafness, bone marrow suppression, endocrine disorders, pulmonary embolism, myocarditis, enteritis, acute pancreatitis, acute renal failure, gastrointestinal events (bleeding, intestinal perforation, acute pancreatitis, etc.) or a decrease of 10% or more from baseline by the Barthel index. |
Countries
China
Outcome results
None listed